Aug 12, 2022
Applied Therapeutics Reports Second Quarter 2022 Financial Results
Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones
May 19, 2022
Applied Therapeutics to Present at the UBS Global Healthcare Conference
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in
May 12, 2022
Applied Therapeutics Reports First Quarter 2022 Financial Results
Continued progress in three Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2022 NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug
Displaying 1 - 10 of 15


Print Page
Print Page
Email Alerts
RSS Feeds
RSS Feeds
Contact IR
Contact IR
AP_logo_KO
linkedin
facebook
twitter

©2022 Applied Therapeutics All Rights Reserved

linkedin
facebook
twitter
AP_logo_KO

©2022 Applied Therapeutics All Rights Reserved